Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 801–900 of 963
Dødelighet ved type 1-diabetes
Helsingen, L. M. (2015) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.15.0080
Neue Technologien in der Diabetologie: Wie weit ist es noch bis zum Closed-loop-System?
Freckmann, G. (2015) · Der Internist
Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1339-4
Miller, R. G. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Aspects of the Pre-Diabetic Period in Type 1 Diabetes
Åkerman, L. (2016) · Linköping University medical dissertations · doi:10.3384/disss.diva-132171
Modem means for the treatment of atrial fibrillation in diabetic patients
Кучеренко, О. Д., Brek, V. V., Шелест, Б. О., & Kovaleva, Y. A. (2016) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2016-94-3-165-171
Diabetische Nephropathie up to date
Werth, S. C., & Steinhoff, J. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0788-1
Diabetische Nephropathie up to date: Diagnostik und Therapie
Werth, S. C., & Steinhoff, J. (2017) · CME · doi:10.1007/s11298-017-5977-2
Using abrupt change detection to categorize glucose variability of Type 1 diabetes patients
Lev, Z., Wheeler, C., Gardner, G., & Flower, A. A. (2017) · Systems and Information Engineering Design Symposium · doi:10.1109/sieds.2017.7937724
Kyriacou, A., Evans, J. M. M., & Kyriacou, A. (2017) · Endocrine Abstracts · doi:10.1530/endoabs.49.ep481 · Cited by 1
Rölver, K., & Lange, K. (2017) · Diabetes aktuell · doi:10.1055/s-0043-113054
Aktueller Stand und Perspektiven der Inselzell-Xenotransplantation
Seißler, J. (2017) · Info Diabetologie · doi:10.1007/s15034-017-1129-8
Is HbA1c still the Gold Standard for Glycemic Control?
Borz, V. (2017) · Journal of Diabetic Complications & Medicine · doi:10.4172/2475-3211.1000e103 · Cited by 1
Oral diabetes treatments and cardiovascular disease
Saulnier, P., & Hadjadj, S. (2018) · doi:10.1093/med/9780198784906.003.0040_update_001
Fries, C. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0343-x
Bujang, M. A., Tiong, X. T., Sapri, F. E., Ismail, M., Mustafa, F. I., & Hamid, A. M. A. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0686-2 · Cited by 1
“In a Swedish study, patients with T1DM have twice the risk of death from cardiovascular event even with good glycemic control [11].”
BackgroundModern approaches to achieving the optimal metabolic control in children with type 1 diabetes
Solntsava, A. V., & Volkava, N. V. (2018) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/de2018-2-16
Fall 15: Spätschäden – 70 Jahre, ♂, DM Typ 1
Kopf, S. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_15
Fall 17: Spätschäden – 35 Jahre, ♂, DM Typ 1, Bluthochdruck
Kihm, L. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_17
Fall 19: Spätschäden – 30 Jahre, ♀, DM Typ 1, Mikroalbuminurie
Kihm, L. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_19
Diabetes mellitus Typ 1 bei Kindern und Jugendlichen: Stoffwechselkontrolle und Folgeerkrankungen
Holder, M., & von Sengbusch, S. (2019) · Springer Reference Medizin · doi:10.1007/978-3-662-57309-9_16
Glycaemic control in pregnancies complicated by type 1 diabetes
Stewart, Z. A. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.23269 · Cited by 1
Kardiovaskuläres Risiko und chronische Entzündung
Milatz, F. (2019) · Arthritis und Rheuma · doi:10.1055/a-0860-9477
Coutant, R., Tubiana‐Rufi, N., Leroy, C., Lefebvre, C., Gueorguieva, I., Cartigny, M., Lablanche, S., & Benhamou, P. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00012-4
Dépistage des complications du diabète de type 1 chez l’enfant
Briet, C., & Allix, I. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00016-1
(New antidiabetics and cardiovascular safety in the light of clinical trials)
Ječmenová, M., Václavík, J., & Táborský, M. (2019) · Cor et Vasa · doi:10.33678/cor.2019.008
LA MALATTIA RENALE CRONICA NON-ALBUMINURICA NEL DIABETE MELLITO TIPO 1
Garofolo, M., Daniele, G., & Penno, G. (2019) · il Diabete · doi:10.30682/ildia1904a
Disciplina Nursing, U. D. M. Ş. F. „. T. P., Popa, A. D., Antohe, I., & Disciplina Nursing, U. D. M. Ş. F. „. T. P. (2019) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2019.2.7
Glycaemic variability. What glycated haemoglobin hides
Arévalo‐Lorido, J. C., & Carretero‐Gómez, J. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.03.006
Minami, T., Shirakawa, J., Kameda, A., Suzuki, Y., Watanabe, K., Yamada, T., Hiiragi, H., Takeda, S., Takahashi, M., & Terauchi, Y. (2020) · Diabetology International · doi:10.1007/s13340-020-00452-8
Mesa 1: Diabetes mellitus tipo 1 y enfermedad cardiovascular
González, L., Chertkoff, A., Burgos, M. A., Trifone, L., Sanabria, H. D., Koleff, C. K., Roccatagliata, L. E., Rama, V., Pomares, M. L., Suppo, M., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.251 · Cited by 1
Momani, A. (2019) · Research Explorer (The University of Manchester)
Bolado, F. (2018) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/42456
Islet-Derived eATP Fuels Autoreactive CD8 Cells and Facilitates the Onset of Type 1 DiabetesPreprint
Tezza, S., Nasr, M. B., Vergani, A., D’Addio, F., Usuelli, V., Falzoni, S., Bassi, R., Dellepiane, S., Fotino, C., Rossi, C., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155651
Cardioprotective Effects of Soluble Epoxide Hydrolase Inhibition Following Myocardial Infarction
Jamieson, K. L. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-ha5a-nh95 · Cited by 1
Variabilidad glucémica. Lo que la glicada esconde
Arévalo‐Lorido, J. C., & Carretero‐Gómez, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.03.004
Descripción del riesgo cardiovascular en pacientes diabéticos tipo 1 en República Dominicana
Martínez, A. G., Vásquez, M., Ferreras, R., Canto, I., & Calderón, K. (2021) · Ciencia y Salud · doi:10.22206/cysa.2021.v5i2.pp87-94
Simonsen, J. R. (2021) · Helda - University of Helsinki Institutional Repository
Popov, K., Bondarenko, I. Z., Biryukova, E. V., Shatskaya, O. A., Tarbaeva, N. V., Vorontsov, А. V., & Shestakova, M. V. (2021) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2021-36-3-51-58
Perinatal risk factors for type 1 diabetes in children and adolescents
Lindell, N. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-180918 · Cited by 1
Conservative shock filtering of numerical solutions of the 1-D Euler equations
Breuß, M. (2006) · Publications of the UdS (Saarland University) · doi:10.22028/d291-26341 · Cited by 1
El ordenamiento juridico informativo en España
Guanter, J. M. D. (1990) · Situación: revista de coyuntura económica · Cited by 2
Kardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1
Lee-Barkey, Y. H., Stratmann, B., & Tschöpe, D. (2022) · Der Diabetologe · doi:10.1007/s11428-021-00854-5
Krankheitsparameter auf dem Prüfstand: Dogmatisierung des HbA1c
Kopf, S., & Nawroth, P. P. (2015) · Deutsches Ärzteblatt · doi:10.3238/persdia.2015.10.23.01
Hämoglobin A 1c: Die heutige Rolle für die therapeutische Entscheidung
Müller‐Wieland, D., & Marx, N. (2019) · Deutsches Ärzteblatt · doi:10.3238/persdia.2019.10.25.02
Therapy of Type 1 Diabetes Mellitus
Omura, E., & Peters, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-1 · Cited by 1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_43
Praveen, P. A., Amutha, A., Singh, K., Prabhakaran, D., Narayan, K. M. V., Mohan, V., & Tandon, N. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109863
JENDLE, J. H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221091842
Patient Experience with Amputation or Limb Loss : Literature ReviewPreprint
Isworo, A., & Pandin, M. G. R. (2022) · medRxiv · doi:10.1101/2022.04.23.22274207
Diabetes mellitus Typ 1 bei Kindern und Jugendlichen: Stoffwechselkontrolle und Folgeerkrankungen
Holder, M., & von Sengbusch, S. (2018) · Springer Reference Medizin · doi:10.1007/978-3-662-52794-8_16-1
Aspectos clínicos y diagnósticos de la diabetes infantil
Louvigné, M., Decrequy, A., Donzeau, A., Bouhours‐Nouet, N., & Coutant, R. (2018) · EMC - Pediatría · doi:10.1016/s1245-1789(17)88072-0 · Cited by 10
Aronow, W. S. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727521391.793538499
Folgeerkrankungen und Prognose des Typ-1-Diabetes
Kordonouri, O., Danne, T., & Lange, K. (2016) · Springer eBooks · doi:10.1007/978-3-662-48067-0_12
JENDLE, J. H., Ampudia‐Blasco, F. J., Füchtenbusch, M., & Pozzilli, P. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.1.1.12 · Cited by 2
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.06.003 · Cited by 1
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00936-y
Left ventricular diastolic dysfunction in type 1 diabetes mellitus: the importance of being earlier
Rigo, F. (2022) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-022-02647-3
Li, H., Bai, S. J., Cao, X., Wu, L., & Zhang, X. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4162445
Marfella, R., Scisciola, L., Onofrio, N. D., Maiello, C., Trotta, M. C., Marfella, L. V., Capuano, A., Panarese, I., Ferraraccio, F., Barbieri, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4168690
Müller‐Wieland, D., & Marx, N. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_12-1
Prise en charge du diabète de type 1 chez les adultes en France : l’étude SAGE
Renard, É., Nevoret, C., Borot, S., Delemer, B., Mohammedi, K., Sultan, A., Bahloul, A., Benkhelil, A., Detournay, B., & Penfornis, A. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.09.001 · Cited by 3
(2022) · Jordan Journal of Biological Sciences · doi:10.54319/jjbs/150304
Prevalence of Cardiovascular Risk Factors in Type 1 Diabetes Mellitus Patients
Bougatf, S., Ali, Z. H., Htira, Y., Jemai, C., Hedfi, I., & Mami, F. B. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0044
Prattichizzo, F., & Ceriello, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00968-4
Blood Pressure Disorders in Diabetic Children and Adolescents
Lurbe, E. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_2
Commentary to "How to Treat Peripheral Arteriovenous Malformations"
Candela, E. (2023) · Angiología · doi:10.20960/angiologia.00486
Anderzén, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180750325
Cywes, R., Kajee, H., Wellington, N., Cucuzzella, M. T., Riley, K., Isaacs, D. M., Pataguana, N., Lake, I., Rauch, L., McKelvey, S., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00010-3
Editorial: Daily challenges around physical exercise, nutrition and medication in type 1 diabetes
Moser, O., & Dovč, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1259535
Secondary Complications: Pancreas Versus Islet Transplantation
Maffi, P., Catarinella, D., & Secchi, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_64
Neubauer‐Geryk, J., Wielicka, M., Kozera, G., & Bieniaszewski, L. (2023) · Biomedicines · doi:10.3390/biomedicines11092591
“Although the mortality risk related to type 1 diabetes has declined by 29% over the past 10 years, it is still estimated to be between two and eight times higher than that of the general population [1,2].”
Krishnamurthy, H. A., Bhangari, V. S., & Sandesh, L. (2023) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2023/11-39
Varkevisser, R. D. M., Mul, D., Aanstoot, H., Wolffenbuttel, B. H. R., & van der Klauw, M. M. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073690 · Cited by 4
The Story of Diabetes and its Causes
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010004
Müller‐Wieland, D., & Marx, N. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_12
Immunotherapies for Type 1 Diabetes
Johannesen, J., & Pociot, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch76
Multimodale kardiovaskuläre Prävention
Müller‐Wieland, D., Verket, M., Brandts, J., Jacobsen, M., Marx, N., Kanna, N. D. D., Balfanz, P., & Schütt, K. S. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_571-1
Metabolic Control, Morbidity and Mortality in Type 1 Diabetes with Onset in Childhood/Adolescence
Samuelsson, J. (2024) · Linköping University medical dissertations · doi:10.3384/9789180755269 · Cited by 1
Managing Heart Disease in Persons with Diabetes
McCrea, D. L. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.10.001
Büyükyılmaz, G., Şahan, Y. Ö., Tehçi, A. K., Özer, E., Özdemiroğlu, N., İnözü, M., Çetin, İ. İ., Gürbüz, F., Boyraz, M., & Bayrakçı, U. S. (2024) · Trends in Pediatrics · doi:10.59213/tp.2024.167
Özde, Ş., Yavuzyılmaz, F., Özel, M. A., Kayapınar, O., Özde, C., Aktüre, G., & Arslanoğlu, İ. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030935
Understanding Self‐Care Patterns in Adults With Type 1 Diabetes: Insights From a Mixed Methods Study
MATUS, A. M., Matura, L. A., Cronholm, P. F., Rickels, M. R., & Riegel, B. J. (2025) · Journal of Advanced Nursing · doi:10.1111/jan.16868
“%) shown to reduce the risk for micro-and macrovascular complications of T1D (Lind et al. 2014).”
Parajuli, S., Mandelbrot, D. A., Stratta, R. J., Kandaswamy, R., Parsons, R. F., Singh, N. K., Gruessner, A. G., Kaufman, D. B., & Odorico, J. S. (2025) · Transplantation · doi:10.1097/tp.0000000000005390
Shakeela, K., & Rekha (2025) · i-manager’s Journal on Educational Psychology · doi:10.26634/jpsy.18.3.21185
Ritsinger, V., Gunnarsson, R., Melin, E. O., Hillman, M., Stogianni, A., Holmberg, S., Johansson, K., Neumark, A.-S. N., Krol, H., Rööst, M., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095630
Clasificación fenotípica de la diabetes: un enfoque personalizado para la práctica farmacéutica
García, J. (2025) · Farmacéuticos Comunitarios · doi:10.33620/fc.2173-9218.(2025).23 · Cited by 3
Factors Involved in the Progression of Preclinical Atherosclerosis in People with Type 1 Diabetes
Viñals, C., Conget, I., Granados, M., Solà, C., Ayala, D., Mesa, A., Serés‐Noriega, T., Doménech, M., Perea, V., Blanco, J., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176004 · Cited by 1
“Cardiovascular risk (CVR) escalates with each uncontrolled risk factor, even when glycemic control is adequate, highlighting the need for comprehensive CVD risk management [4,5].”
Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative Study
Karpen, S. R., Mellor, R., DiMeglio, L. A., Senior, P. A., Sherr, J. L., Bussberg, C., Mansfield, C. A., Marinac, M., & Myers, K. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01783-y · Cited by 2
Lipid metabolism in type 1 diabetes initiation and progression to vascular disease
Borowsky, N. S., Michel, R., Hirani, K., & Vendrame, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00028-2
Bandyopadhyay, S., Dey, R., Chakraborty, P., Jharwal, C., Chakraborty, P., & Pandit, M. (2025) · Cureus · doi:10.7759/cureus.94773 · Cited by 1
Стратификация кардиоваскулярного риска у пациентов молодого возраста с сахарным диабетом 1-го типа
Shepelkevich, A. P., Баалбаки, Д. Д., Юреня, Е. В., Отливанчик, Е. С., & Дыдышко, Ю. В. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.5.002
Fridolfsson, C., Blomstrand, P., Engvall, J. E., & Thegerström, J. (2025) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.70125
“Achieving a mediocre result on the exercise test despite a subjective moderate to high reported physical activity level or a high perceived effort on the Borg scale might thus be interpreted as an early sign of exercise intolerance, that is, a precursor stage of a recognized symptom of CAN (Vinik et al. 2013), at leas…”
InfluentialNagulagari, T., Novicoff, W. M., Lyons, G. R., Valenzuela, M. C. S., Reyes, N. A., Brown, S. A., & Love, K. M. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0075
Müller‐Wieland, D., & Marx, N. (2024) · Springer eBooks · doi:10.1007/978-3-662-69938-6_12
Folgeerkrankungen und Prognose des Typ-1-Diabetes
Danne, T., Kordonouri, O., & Lange, K. (2014) · Springer eBooks · doi:10.1007/978-3-642-24645-6_7 · Cited by 1
Amor, A. J., Castelblanco, E., Hernández, M., Giménez, M., Granado-Casas, M., Blanco, J., Soldevila, B., Esmatjes, E., Conget, I., Alonso, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12782625
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.